Glucosylceramidase activity (measured in the presence of sodium taurocholate) in Gaucher disease, Parkinson’s disease with GBA mutation and non-manifesting carrier lines was significantly lower than controls (Fig. 1C). This evidence concerns the gene GBA1 and Parkinson disease.